Journal
CANCER LETTERS
Volume 442, Issue -, Pages 409-428Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2018.10.042
Keywords
Triple-negative breast cancer; Immunotherapy; Research progress
Categories
Funding
- Natural Science Foundation of China [81872160]
- Capital Public Health Education, Beijing Science and Technology Program [Z171100000417028]
- Chinese Academy of Medical Sciences Initiative for Innovative Medicine [2017-I2M-3-020]
Ask authors/readers for more resources
Triple-negative breast cancer (TNBC) refers to cancers that are low in expression of the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). TNBC tends to behave more aggressively than other types of breast cancer. Unlike other breast cancer subtypes (ie, ER-positive, HER2-positive subtypes), there are no approved targeted treatments available, other than the administration of chemotherapy. Immunotherapy is a new kind of treatment approach for TNBC when compared with the surgical treatment, chemotherapy, endocrine therapy, and molecular targeting therapy. The present article reviews the research progresses of immunotherapy for TNBC in recent years. The full text structure covers molecular classification of TNBC, active immunotherapy of TNBC, passive immunotherapy of TNBC, oncolytic immunotherapy and the prospect of immunotherapy for TNBC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available